- Home
- / Taibang Biologic Group
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Taibang Biologic Group financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Total Funding
$9.6 M
Revenue
$503.7 M
FY, 2019
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 |
|---|---|---|
| Revenue | 466.9M | 503.7M |
| Cost of goods sold | 123.6M | 150.0M |
| Gross profit | 343.3M | 353.7M |
| Gross profit margin, % | 70.2% | |
| Operating expense total | 173.9M | 165.4M |
| Depreciation and amortization | 23.2M | 24.6M |
| EBITDA | 171.8M | 189.9M |
| EBITDA margin, % | 37.7% | |
| EBIT | 152.6M | 170.7M |
| EBIT margin, % | 33.9% | |
| Interest income | 13.7M | 21.3M |
| Interest expense | 338.0K | 558.0K |
| Pre tax profit | 166.0M | 191.5M |
| Income tax expense | 18.0M | 28.1M |
| Net Income | 148.0M | 163.4M |